Abstract
Background Frailty is a geriatric syndrome characterized by chronic inflammation and metabolic insufficiency that creates vulnerability to poor outcomes with aging. We hypothesize that geroscience interventions, which target mechanisms of aging, could ameliorate frailty. Metabolites such as ketone bodies are candidate geroscience interventions, having pleiotropic effects on inflammo-metabolic aging mechanisms. Ketone esters (KEs) induce ketosis without dietary changes, but KEs have not been studied in an older adult population. Our long-term goal is to examine if KEs modulate geroscience mechanisms and clinical outcomes relevant to frailty in older adults.
Objectives The primary objective of this randomized, placebo-controlled, double-blinded, parallel-group, pilot trial is to determine tolerability of 12-weeks of KE ingestion in a generalizable population of older adults (≥ 65 years). Secondary outcomes include safety and acute blood ketone kinetics. Exploratory outcomes include physical function, cognitive function, quality of life, aging biomarkers and inflammatory measures.
Methods Community-dwelling adults who are independent in activities of daily living, with no unstable acute medical conditions (n=30) will be recruited. The study intervention is a KE or a taste, appearance, and calorie matched placebo beverage. Initially, acute 4-hour ketone kinetics after 12.5g or 25g of KE consumption will be assessed. After collection of baseline safety, functional, and biological measurements, subjects will randomly be allocated to consume KE 25g or placebo once daily for 12-weeks. Questionnaires will assess tolerability daily for 2-weeks, and then via phone interview at bi-monthly intervals. Safety assessments will be repeated at week 4. All measures will be repeated at week 12.
Conclusion This study will evaluate feasibility, tolerability, and safety of KE consumption in older adults and provide exploratory data across a range of geroscience-related endpoints. This data will inform design of larger trials to rigorously test KE effects on geroscience mechanisms and clinical outcomes relevant to frailty.
Competing Interest Statement
The principal investigator (Dr. Newman), Dr. Brianna Stubbs, and the Buck Institute hold shares in BHB Therapeutics. Drs. Newman and Stubbs are inventors on patents relating to the use of ketone bodies that are assigned to The Buck Institute. All other authors have no conflicts to declare. Individual and institutional extensive conflict management plans were developed and approved by the Buck Institute and the IRB. Actions and decisions important to subject safety and study integrity are carried out by parties with no potential financial conflict. Participant consent is obtained by licensed registered nurses who have no financial conflict. Decisions on subject enrollment, continuation, and discontinuation are made by independent medical officers unaffiliated with Buck Institute and with no financial conflict. Data analysis for the primary outcome is carried out by an independent statistician with no financial conflict. Study staff, including the principal investigator, will maintain blinding through study completion unless unblinding is required for safety concerns.
Clinical Trial
NCT05585762
Funding Statement
Funding for BIKE is provided by philanthropic donations from Dr James B. Johnson and from members of the Buck Institute Impact Circle. Dr Johnson assisted with conceptualization of the study and reviewed this manuscript but has no further role in study design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications. The Buck Institute Impact Circle has no role in conceptualization, study design, management, data collection, analysis, interpretation of data, decision to submit publications, review, or writing of publications. Dr Newman's participation in the study is supported by Buck Institute institutional funds. Dr Brianna Stubbs' participation in the study is supported by supported by the NIH (NIA) under award number K01AG078125. The KE intervention is provided gratis by BHB Therapeutics Ltd (Ireland). BHB Therapeutics also arranged for manufacture of the matched placebo, paid from BIKE study funds. BHB Therapeutics markets formulated KE beverages to consumers. BHB Therapeutics provided no funding for the study, and has no role in the design, management, data collection, analysis, interpretation of data, decision to submit publications, or writing of publications.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study will be conducted according to the guidelines of the Declaration of Helsinki (2004), and the first version of the study documents were approved by Advara IRB on September 28, 2022 (current version was approved 17th January 2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- 1-RM
- 1 Repetition Maximum
- ADL
- Activities of Daily Living
- AEs
- Adverse Events
- BDO
- (R)-1,3-butanediol
- BH-BD
- Bis-hexanoyl (R)-1,3-butanediol
- BHB
- Beta-hydroxybutyrate
- BMI
- Body Mass Index
- BO-BD
- Bis-octanoyl (R)-1,3-butanediol
- BTQ
- Beverage tolerability questionnaire
- CSHA
- Canadian Study of Health and Aging
- CRF
- Case Report Form
- DSST
- Digit Symbol Substitution Test
- IADL
- Instrumental Activities of Daily Living
- ITT
- Intention to treat
- KEs
- Ketone Esters
- MoCA
- Montreal Cognitive Assessment
- PLA
- Placebo
- PP
- Per protocol
- QoL
- Quality of Life
- SASP
- Senescence-associated secretory phenotype
- SPPB
- Short Physical Performance Battery
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.